The bid by private equity firm MBK Partners for AsiaPharm was in focus yesterday when Templeton Asset Management president Mark Mobius said the fund was ônot convinced by the offerö. Mobius says the offer price ôseverely undervalues AsiaPharm and is highly disadvantageous to minority shareholdersö. He also claims that full disclosure about the agreement between MBK and AsiaPharm's directors has not been provided to minority shareholders.
Templeton was responding to a tender offer announced...
¬ Haymarket Media Limited. All rights reserved.